Literature DB >> 35077947

Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Chetna Dureja1, Abiola O Olaitan1, Julian G Hurdle2.   

Abstract

The evolution of antimicrobial resistance in Clostridioides difficile has markedly shaped its epidemiology and detrimentally impacted patient care. C. difficile exhibits resistance to multiple classes of antimicrobials, due to accumulation of horizontally acquired resistance genes and de novo mutations to drug targets. Particularly worrying is that declines in clinical success of firstline CDI antimicrobials coincide with the spread of strains that are more resistant to these drugs. Yet, there is still much to learn regarding the prevalence of genetic elements in clinical isolates, their molecular mechanisms, and the extent to which this information can be translated to develop molecular diagnostics that improve antimicrobial prescribing and antimicrobial stewardship approaches for CDI. Thus, this perspective discusses current understanding and knowledge gaps of antimicrobial resistance mechanisms in C. difficile, emphasizing on CDI therapies.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35077947      PMCID: PMC9064893          DOI: 10.1016/j.mib.2022.01.004

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.584


  70 in total

1.  Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates.

Authors:  Wan-Jou Shen; Aditi Deshpande; Kirk E Hevener; Bradley T Endres; Kevin W Garey; Kelli L Palmer; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

2.  The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome.

Authors:  Mohammed Sebaihia; Brendan W Wren; Peter Mullany; Neil F Fairweather; Nigel Minton; Richard Stabler; Nicholas R Thomson; Adam P Roberts; Ana M Cerdeño-Tárraga; Hongmei Wang; Matthew T G Holden; Anne Wright; Carol Churcher; Michael A Quail; Stephen Baker; Nathalie Bason; Karen Brooks; Tracey Chillingworth; Ann Cronin; Paul Davis; Linda Dowd; Audrey Fraser; Theresa Feltwell; Zahra Hance; Simon Holroyd; Kay Jagels; Sharon Moule; Karen Mungall; Claire Price; Ester Rabbinowitsch; Sarah Sharp; Mark Simmonds; Kim Stevens; Louise Unwin; Sally Whithead; Bruno Dupuy; Gordon Dougan; Bart Barrell; Julian Parkhill
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

3.  Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Authors:  Farah Babakhani; Abraham Gomez; Nikki Robert; Pamela Sears
Journal:  J Med Microbiol       Date:  2011-02-24       Impact factor: 2.472

4.  Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: a mosaic framework containing 83 mutations.

Authors:  A Dessen; N Mouz; E Gordon; J Hopkins; O Dideberg
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

5.  Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis.

Authors:  Timothy Lawes; José-María Lopez-Lozano; Cesar A Nebot; Gillian Macartney; Rashmi Subbarao-Sharma; Karen D Wares; Carolyn Sinclair; Ian M Gould
Journal:  Lancet Infect Dis       Date:  2016-11-04       Impact factor: 25.071

Review 6.  Can we identify patients at high risk of recurrent Clostridium difficile infection?

Authors:  C P Kelly
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

7.  c-di-AMP is a new second messenger in Staphylococcus aureus with a role in controlling cell size and envelope stress.

Authors:  Rebecca M Corrigan; James C Abbott; Heike Burhenne; Volkhard Kaever; Angelika Gründling
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

8.  A Role for Tetracycline Selection in Recent Evolution of Agriculture-Associated Clostridium difficile PCR Ribotype 078.

Authors:  Kate E Dingle; Xavier Didelot; T Phuong Quan; David W Eyre; Nicole Stoesser; Charis A Marwick; John Coia; Derek Brown; Sarah Buchanan; Umer Z Ijaz; Cosmika Goswami; Gill Douce; Warren N Fawley; Mark H Wilcox; Timothy E A Peto; A Sarah Walker; Derrick W Crook
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

9.  Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection.

Authors:  Anne J Gonzales-Luna; Abiola O Olaitan; Wan-Jou Shen; Aditi Deshpande; Travis J Carlson; Kierra M Dotson; Chris Lancaster; Khurshida Begum; M Jahangir Alam; Julian G Hurdle; Kevin W Garey
Journal:  Open Forum Infect Dis       Date:  2021-07-08       Impact factor: 3.835

10.  Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile.

Authors:  Ilse M Boekhoud; Igor Sidorov; Sam Nooij; Céline Harmanus; Ingrid M J G Bos-Sanders; Virginie Viprey; William Spittal; Emma Clark; Kerrie Davies; Jane Freeman; Ed J Kuijper; Wiep Klaas Smits
Journal:  J Antimicrob Chemother       Date:  2021-04-20       Impact factor: 5.790

View more
  1 in total

1.  Evaluation of Derivatives of (+)-Puupehenone against Clostridioides difficile and Other Gram-Positive Bacteria.

Authors:  Michael A Johnstone; Alexander D Landgraf; Anshupriya Si; Steven J Sucheck; William T Self
Journal:  ACS Omega       Date:  2022-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.